{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:51:33Z","timestamp":1792068693522,"version":"4.4.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02400-3","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:17:24Z","timestamp":1792066644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ciprocopan: First Approval"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2400_CR1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2400_CR2","first-page":"727","volume":"45","author":"Red Blood Cell Disease Group CSoHCMA","year":"2024","unstructured":"Red Blood Cell Disease Group CSoHCMA. Guidelines for the diagnosis and management of paroxysmal nocturnal hemoglobinuria (2024). Zhonghua Xue Ye Xue Za Zhi. 2024;45(8):727\u201337.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2400_CR3","unstructured":"Haisco. Ciprocopan succinate tablets: Chinese prescribing information. 2026. https:\/\/www.haisco.com\/uploads\/image\/20260730\/6a6b16221fef5.pdf. Accessed 4 Sept 2026."},{"key":"2400_CR4","unstructured":"National Medical Products Administration. NMPA approval notice [media release]. 23 July 2026. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20260723091948184.html."},{"key":"2400_CR5","unstructured":"Haisco. Haisco enters into exclusive license agreement with Nuvectis for two drug candidates in oncology and complement indications [media release]. 23 June 2026. https:\/\/www.prnewswire.com\/news-releases\/haisco-enters-into-exclusive-license-agreement-with-nuvectis-for-two-drug-candidates-in-oncology-and-complement-indications-302807803.html."},{"issue":"e70281","key":"2400_CR6","first-page":"1","volume":"18","author":"Y Dai","year":"2025","unstructured":"Dai Y, Wu F, Ni S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of HSK39297 in Chinese healthy subjects: a phase 1 clinical trial. Clin Transl Sci. 2025;18(e70281):1\u201312.","journal-title":"Clin Transl Sci"},{"key":"2400_CR7","unstructured":"Gong Y, Wang S, Zhang L, et al. A phase III study of a head-to-head comparison of a factor B inhibitor HSK39297 versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition [abstract no. S181 plus presentation]. HemaSphere. 2026;10(Suppl 1):195\u20136."},{"key":"2400_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000004198","author":"Y Gong","year":"2026","unstructured":"Gong Y, Zhang L, Zhu Z, et al. Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria. Chin Med J (Engl). 2026. https:\/\/doi.org\/10.1097\/cm9.0000000000004198.","journal-title":"Chin Med J (Engl)"},{"key":"2400_CR9","unstructured":"Xu G, He G, Zhang L, et al. Efficacy and safety of switching to oral HSK39297 monotherapy in paroxysmal nocturnal hemoglobinuria patients with persistent anemia despite anti-C5 therapy: a phase 3 study (HSK39297-302) [abstract no. PS1786 plus poster]. HemaSphere. 2026;10(Suppl 1):3106\u20137."},{"key":"2400_CR10","doi-asserted-by":"crossref","unstructured":"Lv J, Liu J, Pei H, et al. Efficacy and safety of HSK39297, a once-daily oral CFB inhibitor, in patients with primary immunoglobulin A nephropathy: a randomized, double-blind, placebo-controlled phase II trial [abstract no. WCN26-5558 ]. Kidney Int Rep. 2026;11(4, Suppl):36\u20137.","DOI":"10.1016\/j.ekir.2026.104480"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02400-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02400-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:17:25Z","timestamp":1792066645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02400-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":10,"alternative-id":["2400"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02400-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"14 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Simon Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}